Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study

Scarselli, Gianfranco; Bargelli, Gianni; Taddei, Gian Luigi; Marchionni, M; Peruzzi, Elena; Pieralli, Annalisa; Mattei, Alberto; Buccoliero, Anna Maria; Fambrini, Massimiliano

doi:10.1016/j.fertnstert.2010.07.1044

Cited by 12 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[65] As recently highlighted by Scarselli et al, who followed patients for over 15 years, LNG-IUS represents an option to treat hyperplasia and prevent endometrial carcinoma in at least 85% of patients. [66] Consistent with that study, in order to support stable regression over long periods of time, we recommend continued preventive LNG-IUS use on a life-long basis using a suitable LNG-IUS as the uterine cavity is often very small. Annual assessment of the endometrial thickness by ultrasound is probably sufficient unless vaginal bleeding occurs.…”

Section: Rationale For Prevention Using Levonorgestrel-releasing Intrsupporting

confidence: 73%

Endometrial Cancer Prevention with Levonorgestrel-Releasing Intrauterine System

Wildemeersch¹,

Jóźwik²,

Jóźwik³

2015

Contemporary Gynecologic Practice

View full text Add to dashboard Cite

show abstract

Section: Rationale For Prevention Using Levonorgestrel-releasing Intrsupporting

confidence: 73%

Endometrial Cancer Prevention with Levonorgestrel-Releasing Intrauterine System

Wildemeersch¹,

Jóźwik²,

Jóźwik³

2015

Contemporary Gynecologic Practice

View full text Add to dashboard Cite

show abstract

“…The use of the LNG-IUS in the management of postmenopausal obese women with EH is well established 4. In a multicentre retrospective study by Morelli et al ,5 histological regression of EH was observed in 79.4% and 97.5% cases at 12 and 36 months, respectively.…”

Section: Discussionmentioning

confidence: 99%

Rare case of coexisting ovarian Brenner tumour and ovarian stromal hyperplasia presenting with persistent endometrial hyperplasia following treatment with levonorgestrel-intrauterine system

Mok

Chin

2022

BMJ Case Rep

View full text Add to dashboard Cite

Endometrial hyperplasia (EH) is a precursor of endometrial cancer. It arises in an environment of unopposed oestrogen. Treatment is based on a combination of weight management, diet and exercise, and the use of progestogens either via a levonogestrel-intrauterine system (LNG-IUS) or orally. The LNG-IUS is the first-line recommendation for EH without atypia. Recurrences are rare, and any recurrences despite prolonged treatment and control of risk factors necessitate a thorough consideration of other oestrogenic sources. This case report presents a rare case of a coexisting ovarian Brenner tumour and ovarian stromal hyperplasia in a menopausal patient in her 50s with recurrent EH despite earlier regression. The above histology may have provided the additional oestrogenic influence. This patient subsequently underwent a definitive hysterectomy and bilateral salpingo-oophorectomy (BSO). It is important to maintain a high index of suspicion for potential oestrogenic influences in cases of refractory EH that are not identifiable on imaging. BSO should be considered at the time of hysterectomy in such cases of unidentified oestrogenic foci.

show abstract

“…The intrauterine system has been proved to be effective in over 85% of patients with simple endometrial hyperplasia although the authors recommend long term follow up with periodic biopsies for up to 2 years (Scarselli et al, 2011).…”

Section: Comparison With Other Treatments Of Menorrhagiamentioning

confidence: 99%

Menorrhagia and the Levonorgestrel Intrauterine System

Miheso¹

2012

Hysterectomy

View full text Add to dashboard Cite

Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study

Cited by 12 publications

References 13 publications

Endometrial Cancer Prevention with Levonorgestrel-Releasing Intrauterine System

Endometrial Cancer Prevention with Levonorgestrel-Releasing Intrauterine System

Rare case of coexisting ovarian Brenner tumour and ovarian stromal hyperplasia presenting with persistent endometrial hyperplasia following treatment with levonorgestrel-intrauterine system

Menorrhagia and the Levonorgestrel Intrauterine System

Contact Info

Product

Resources

About